Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALK | Q9UM73 | 16/20 | 0.52 |
| ▸ | PDPK1 | O15530 | 2/20 | 0.50 |
| ▸ | TNIK | Q9UKE5 | 1/20 | 0.49 |
| ▸ | PIM1 | P11309 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9278508 | 0.81 | ALK (0.54) | ALKPDPK1TNIK | |
| SCHEMBL17785592 | 0.81 | CSNK2A1 (0.51) | PIM1 | |
| SCHEMBL4069914 | 0.80 | ALK (0.53) | ALKPDPK1 | |
| SCHEMBL4072944 | 0.79 | PDPK1 (0.50) | ALKPDPK1TNIK | |
| SCHEMBL3591973 | 0.77 | PDPK1 (0.49) | ALKPDPK1 | |
| SCHEMBL28512236 | 0.77 | ALK (0.54) | ALKPDPK1TNIK | |
| SCHEMBL720228 | 0.77 | ALK (0.57) | ALKPDPK1TNIK | |
| SCHEMBL20950738 | 0.77 | PIM1 (0.46) | ALKPIM1 | |
| SCHEMBL16344211 | 0.77 | PDPK1 (0.58) | ALKPDPK1 | |
| SCHEMBL3833314 | 0.74 | ALK (0.52) | ALKPDPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2081937-B1 | TRIAZOLOPYRIDAZINE PROTEIN KINASE MODULATORS | SGX PHARMACEUTICALS INC (US) | 2012-09-12 | — | — | EP | disclosed |
| US-8071581-B2 | Triazolopyridazine protein kinase modulators | SGX PHARMACEUTICALS, INC. (US) | 2011-12-06 | — | — | US | disclosed |
| US-20100120739-A1 | TRIAZOLOPYRIDAZINE PROTEIN KINASE MODULATORS | SGX PHARMACEUTICALS, INC. | 2010-05-13 | — | — | US | disclosed |
| EP-2081937-A2 | TRIAZOLOPYRIDAZINE PROTEIN KINASE MODULATORS | SGX Pharmaceuticals, Inc. (US) | 2009-07-29 | — | — | EP | disclosed |
| WO-2008051805-A2 | TRIAZOLO-PYRIDAZINE PROTEIN KINASE MODULATORS | SGX PHARMACEUTICALS, INC. (US) | 2008-05-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100120739-A1 | TRIAZOLOPYRIDAZINE PROTEIN KINASE MODULATORS | MAP4K5, MAPKAPK5, MAP4K2 | ALK 924/4885PDPK1 86/4885TNIK 144/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.